It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

Abby Smith, 40, a NHS manager from Reading, has the rare autoimmune disease myasthenia gravis, which means she needs her ...

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

But one of the rarest muscular disorders is also one of the most concerning. It's called myasthenia gravis and affects only about 37 out of every 100,000 people in the United States. Despite being ...

Myasthenia Gravis is a long-term, autoimmune condition in which the communication between muscles and nerves is impaired due to the production of certain antibodies resulting in voluntary muscle ...

This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...

Welcome, everyone. I'm Dr. John Whyte, the Chief Medical Officer at WebMD. Today, I want to discuss myasthenia gravis. It's a rare autoimmune neuromuscular disease that causes weakness and fatigue ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Please provide your email address to receive an email when new articles are posted on . The FDA has granted priority review to a Biologics License Application for nipocalimab to treat individuals ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...